{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:03:09Z","timestamp":1785430989402,"version":"3.56.0"},"posted":{"date-parts":[[2026,7,27]]},"group-title":"Cancer Biology","reference-count":42,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["CA238274"],"award-info":[{"award-number":["CA238274"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CA272424"],"award-info":[{"award-number":["CA272424"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["CA273964"],"award-info":[{"award-number":["CA273964"]}]},{"award":["DICR INTR-24-1297273-01-DICR INTR"],"award-info":[{"award-number":["DICR INTR-24-1297273-01-DICR INTR"]}],"id":[{"id":"https:\/\/ror.org\/02e463172","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CA086862"],"award-info":[{"award-number":["CA086862"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Endometrial cancer (EC), the most common gynecologic malignancy in the USA, has seen limited improvement in patient outcomes over recent decades, underscoring the need for relevant preclinical models. To address EC heterogeneity, we established an integrated platform of patient-derived xenografts (PDXs) and matched patient-derived primary cancer cells (PDCs) for disease modeling and systematic drug sensitivity testing.<\/jats:p>\n                <jats:p>Fresh tumor specimens (n=103) were collected from EC patients to generate PDXs in immunodeficient mice and corresponding PDCs. Fifty-three PDX models were successfully established (52% engraftment rate), with higher success observed in high-grade, recurrent, metastatic tumors (70%), compared with their low-grade counterparts (56%). Histopathologic and immunohistochemical analyses confirmed that PDX tumors faithfully preserved morphology, hormone receptor status, and intertumoral heterogeneity across multiple passages.<\/jats:p>\n                <jats:p>Using 13 PDC models, we performed an unbiased screening of 179 FDA-approved oncology drugs, revealing marked intertumoral variability in drug response. Almost all PDC models exhibited limited sensitivity to NCCN-recommended therapies, highlighting the need for alternative treatment strategies. In contrast, multiple FDA-approved agents including epigenetic modulators, dual PI3-kinase\/HDAC inhibitors, topoisomerase II inhibitors, and proteasome inhibitors demonstrated potent antitumor activity. Importantly, a low-dose combination of the DNA methyltransferase inhibitor 5-azacytidine and the histone deacetylase inhibitor romidepsin significantly suppressed tumor growth across six independent PDX models.<\/jats:p>\n                <jats:p>Together, these findings establish a comprehensive PDX and PDC platform as a robust translational resource. By capturing the histopathologic and molecular diversity of EC and identifying clinically actionable therapeutic advantages, including an epigenetic combination regimen, this study offers a translational resource for preclinical drug evaluation.<\/jats:p>","DOI":"10.64898\/2026.07.24.740568","type":"posted-content","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:45:19Z","timestamp":1785159919000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer"],"prefix":"10.64898","author":[{"given":"Tianyue","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"},{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2784-2656","authenticated-orcid":false,"given":"Ella","family":"Pate","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Rosenmeyer","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mya","family":"Messenger","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee","family":"McSweeney","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Deters","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4264-3567","authenticated-orcid":false,"given":"Maggie","family":"Meehan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Diekema","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-5851","authenticated-orcid":false,"given":"Yiqin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9612-6438","authenticated-orcid":false,"given":"Xiangbing","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"},{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-3068","authenticated-orcid":false,"given":"Shujie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA, 52242"},{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026073009000742000_2026.07.24.740568v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043"},{"key":"2026073009000742000_2026.07.24.740568v1.2","unstructured":"(NCI), N.C.I., SEER Cancer Stat Facts: Uterine Cancer, in https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html, E. Serveillence, and End Results Program, Editor. 2026: National Institute of Health (NIH)."},{"key":"2026073009000742000_2026.07.24.740568v1.3","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-23-0589"},{"issue":"9","key":"2026073009000742000_2026.07.24.740568v1.4","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.xcrm.2022.100738","article-title":"Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer","volume":"3","year":"2022","journal-title":"Cell Rep Med"},{"issue":"6","key":"2026073009000742000_2026.07.24.740568v1.5","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.62347\/HTVU4235","article-title":"Ex vivo platform en route to functional precision medicine: clinical relevance in gynecological cancers","volume":"14","year":"2024","journal-title":"Am J Cancer Res"},{"key":"2026073009000742000_2026.07.24.740568v1.6","doi-asserted-by":"crossref","unstructured":"Moiola, C.P. , et al., Patient-Derived Xenograft Models for Endometrial Cancer Research. Int J Mol Sci, 2018. 19(8).","DOI":"10.3390\/ijms19082431"},{"key":"2026073009000742000_2026.07.24.740568v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.140"},{"key":"2026073009000742000_2026.07.24.740568v1.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3440"},{"key":"2026073009000742000_2026.07.24.740568v1.9","doi-asserted-by":"crossref","unstructured":"Van Nyen, T. , et al., Modeling Endometrial Cancer: Past, Present, and Future. Int J Mol Sci, 2018. 19(8).","DOI":"10.3390\/ijms19082348"},{"key":"2026073009000742000_2026.07.24.740568v1.10","doi-asserted-by":"crossref","unstructured":"Tanaka, T. , et al., Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review. J Clin Med, 2022. 11(9).","DOI":"10.3390\/jcm11092606"},{"key":"2026073009000742000_2026.07.24.740568v1.11","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.neo.2025.101158","article-title":"Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, andtherapeutic target profiling","volume":"64","year":"2025","journal-title":"Neoplasia"},{"key":"2026073009000742000_2026.07.24.740568v1.12","unstructured":"Riss, T. , Moravec, R. , Niles, A. , Duellman, S. , Benink, H. , Worzella, T. , and Minor, L. , Cell Viability Assays, in The Assay Guidance Manuel, G.A. Markossian S , and Baskir H , et al.,, Editor. 2013, National Institute of Health (NIH): Bethesda (MD)."},{"key":"2026073009000742000_2026.07.24.740568v1.13","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac382"},{"issue":"1","key":"2026073009000742000_2026.07.24.740568v1.14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-021-00990-z","article-title":"Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer","volume":"14","year":"2022","journal-title":"Genome Med"},{"key":"2026073009000742000_2026.07.24.740568v1.15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0001"},{"key":"2026073009000742000_2026.07.24.740568v1.16","doi-asserted-by":"crossref","first-page":"1512616","DOI":"10.3389\/fonc.2025.1512616","article-title":"Preclinical research models for endometrial cancer: development and selection of animal models","volume":"15","year":"2025","journal-title":"Front Oncol"},{"key":"2026073009000742000_2026.07.24.740568v1.17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03405-8"},{"issue":"1","key":"2026073009000742000_2026.07.24.740568v1.18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026073009000742000_2026.07.24.740568v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634"},{"key":"2026073009000742000_2026.07.24.740568v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113"},{"key":"2026073009000742000_2026.07.24.740568v1.21","doi-asserted-by":"crossref","unstructured":"Tao, H. , et al., ARID1A deficiency-driven reprogramming of polyamine metabolism promotes endometrial cancer malignancy and immune escape. Cell Death Dis, 2026. 17(1).","DOI":"10.1038\/s41419-026-08722-0"},{"key":"2026073009000742000_2026.07.24.740568v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24211-8"},{"key":"2026073009000742000_2026.07.24.740568v1.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0517-8"},{"issue":"1","key":"2026073009000742000_2026.07.24.740568v1.24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.6004\/jadpro.2022.13.1.4","article-title":"Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer","volume":"13","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"2026073009000742000_2026.07.24.740568v1.25","unstructured":"McMillian, N. , Sambandam, V. , Abu-Rustum, N. , Campos, S. , Amarnath, S. , Arnd, R. , Barber, E. , et al., Uterine Neoplasma, in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2026, National Comprehensive Cancer Network."},{"key":"2026073009000742000_2026.07.24.740568v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.488"},{"key":"2026073009000742000_2026.07.24.740568v1.27","unstructured":"Biologicals, N. FA\u01eas - LC3 and Autophagy. 2026 [cited 2026 6\/16\/2026]."},{"issue":"3","key":"2026073009000742000_2026.07.24.740568v1.28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1080\/15548627.2022.2111083","article-title":"The role of LC3B in autophagy as an RNA-binding protein","volume":"19","year":"2023","journal-title":"Autophagy"},{"key":"2026073009000742000_2026.07.24.740568v1.29","first-page":"135","article-title":"Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma","volume":"8","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2026073009000742000_2026.07.24.740568v1.30","unstructured":"Raedler, L.A ., Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Am Health Drug Benefits, 2016. 9(Spec Feature): p. 102-5."},{"key":"2026073009000742000_2026.07.24.740568v1.31","unstructured":"Medicine, N .L.o. ClinicalTials.gov. 2026 [cited 2026 7\/12]; Available from: https:\/\/clinicaltrials.gov\/."},{"key":"2026073009000742000_2026.07.24.740568v1.32","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875"},{"key":"2026073009000742000_2026.07.24.740568v1.33","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.028310"},{"issue":"1","key":"2026073009000742000_2026.07.24.740568v1.34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12943-025-02444-1","article-title":"Safe delivery of a highly toxic anthracycline derivative through liposomal nanoformulation achieves complete cancer regression","volume":"24","year":"2025","journal-title":"Mol Cancer"},{"key":"2026073009000742000_2026.07.24.740568v1.35","unstructured":"Institute, N.C. , Idarubicin Hydrochloride. 2019, NIH: National Cancer Institute."},{"issue":"6","key":"2026073009000742000_2026.07.24.740568v1.36","first-page":"481","article-title":"DNA methylation in endometrial cancer","volume":"5","year":"2010","journal-title":"Epigenetics"},{"key":"2026073009000742000_2026.07.24.740568v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21991"},{"issue":"6","key":"2026073009000742000_2026.07.24.740568v1.38","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","year":"2024","journal-title":"Lancet Haematol"},{"issue":"16","key":"2026073009000742000_2026.07.24.740568v1.39","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026073009000742000_2026.07.24.740568v1.40","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026073009000742000_2026.07.24.740568v1.41","first-page":"274","article-title":"Endometrial Carcinoma: The Interplay of Genetics and Hormones","volume":"133","year":"2023","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"2026073009000742000_2026.07.24.740568v1.42","doi-asserted-by":"crossref","first-page":"101039","DOI":"10.1016\/j.neo.2024.101039","article-title":"The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)\/2D\/3D culture models harboring EGFR amplification and CDKN2A\/2B homozygous deletions","volume":"57","year":"2024","journal-title":"Neoplasia"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.24.740568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:00:19Z","timestamp":1785427219000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.24.740568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":42,"URL":"https:\/\/doi.org\/10.64898\/2026.07.24.740568","relation":{},"subject":[],"published":{"date-parts":[[2026,7,27]]},"subtype":"preprint"}}